Fennec Pharmaceuticals is trading 9% up at $11.93 after reporting strong second-quarter 2026 results before the August 11, 2026 market open.
- Net product sales reached $17.1 million, up 78% year over year; adjusted EBITDA improved to $2.8 million from a $1.2 million loss.
- Reported earnings were $0.05 per share versus $0.01 expected, and revenue exceeded estimates.
- The gain follows premarket positioning and reflects continued PEDMARK demand, including growth among adolescent and young adult accounts.